SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
|x||QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.|
For the quarterly period ended September 30, 2008
|¨||TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.|
For the transition period from , 200 , to , 200 .
Commission File Number
Stem Cell Therapy International, Inc.
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction of
Incorporation or Organization)
2203 N. Lois Avenue, 9th Floor, Tampa, Florida 33607
(Address of Principal Executive Offices)
(Registrants Telephone Number)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of accelerated filer, large accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
|Large accelerated filer||¨||Accelerated filer||¨|
|Non-accelerated filer||¨||Smaller reporting company||x|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x
Transitional Small Business Disclosure Format (check one): Yes ¨ No x
There were 47,134,258 shares of the Registrants $0.001 par value common stock outstanding as of September 30, 2008.
State the number of shares outstanding of each of the issuers classes of common equity, as of the last practicable date: 47,134,258 as of October 23, 2008.
The Company has filed the attached Form 10-Q Amendment No. 1 in response to an SEC Comment Letter dated January 7, 2009.
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: February 3, 2009
Date: February 3, 2009
|Andrew J. Norstrud|
|Chief Financial Officer|
|ITEM 6.||EXHIBITS AND REPORTS ON FORM 8-K|
|(a)||Exhibit Index. The following exhibits are filed with or incorporated by reference into this quarterly report:|
|31.1||Chief Executive Officer certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.|
|31.2||Chief Financial Officer certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.|
|32||Chief Executive Officer and Chief Financial Officer certification pursuant to 18 U.S.C. Section 1350|